A Phase 2 clinical trial to evaluate the safety and anti-tumor activity of the combination of Vigil EATC and Atezolizumab in women with advanced ovarian cancer.
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2016
At a glance
- Drugs Atezolizumab (Primary) ; Bi-shRNAfurin-GM-CSF-loaded tumour cell vaccine (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Gradalis
- 28 Dec 2016 New trial record
- 21 Dec 2016 According to Gradalis media release, company plans to initiate this trial early in 2017.